$LONA

LeonaBio, Inc. (LONA): Submission of Matters to a Vote of Security Holders

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001620463 0001620463 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,

Original reporting
Published Jun 23, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$LONA
Neutral
high confidence
Mentioned
$LONA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LONANeutralLow
01

Why it matters

The disclosure confirms: (1) election of three Class III directors, (2) ratification of Ernst & Young LLP as independent auditor for FY ending Dec. 31, 2026, and (3) advisory approval of executive compensation plus a non-binding preference for every 3 years for future advisory votes.

02

Market read

Routine governance outcomes; no new financial guidance, deal, or regulatory action is disclosed.

03

What to watch

Check the referenced May 11, 2026 proxy statement for any substantive proposals; this 8-K itself only reports final vote tallies.

Relevance 6/10Novelty 2/10Timing: after-hours/filing date (2026-06-23) for annual meeting vote results

Background

The company held its 2026 Annual Meeting on June 22, 2026 and filed an 8-K under Item 5.07 summarizing final voting results.

Company-level read

Ticker impact

$LONANeutralHigh confidence
Context

LeonaBio filed an 8-K reporting final shareholder vote results, including director elections and ratification of Ernst & Young for FY2026.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to governance/administrative sentiment.

Evidence & confidence

The filing only confirms voting outcomes (board seats, auditor ratification, advisory compensation items) and provides no new guidance, transactions, or enforcement developments.

Market effects

No meaningful read-across to the biotech sector; this is company-specific governance reporting.

None.

None.

Counterpoint

If investors were uncertain about auditor approval or board composition, the confirmed results could reduce uncertainty, but the filing still lacks fundamental catalysts.

Key entities

  • LeonaBio, Inc.

    Nasdaq-listed issuer filing Item 5.07 8-K with final annual meeting vote results.

  • Ernst & Young LLP

    Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

Related articles

$LONAMed

In December 2025, as part of a private placement, LeonaBio, Inc. issued warrants to purchase an aggregate of 23,031,494 shares of its common stock

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. In December 2025, as part of a private placement, LeonaBio, Inc. (the “Company”) issued warrants to purchase an aggregate of 23,031,494 shares of its common stock (the “Series A Common Warrants”). The Series A Common Warrants have an exercise price of $6.3

$LONAMed

LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances

LeonaBio (NASDAQ:LONA) reported a Q2 loss of $0.80 per share, smaller than analysts’ $1.12 forecast. Net loss rose to $19.0 million from $7.0 million a year earlier. Phase 3 ELAINE-3 enrollment nears 600 target, with 495 patients enrolled and topline results expected in H2 2027. Cash fell to $51.1 million from $88.3 million.

$LONAMed

LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline D

$JELDHigh

JELD-WEN launches debt exchange offer for 2027 senior notes

JELD-WEN (NYSE:JELD) launched a debt exchange offer for its $400M 4.875% Senior Notes due 2027, proposing new first lien senior secured notes due 2031. Early participants receive $1,000 of new notes per $1,000 of old notes, while others get $930 or $880. The new notes offer 10.5% or 11.5% interest. 94.5% of note holders agreed to tender by the early deadline, and 70% committed to the new money offering. The company also solicits consents to amend restrictive covenants.

$JELDMedAI 8/10

JELD-WEN Announces Commencement of Exchange Offer and Consent Solicitation for Outstanding 4.875% Senior Notes due 2027

JELD-WEN (JELD) launched an exchange offer for its 4.875% Senior Notes due 2027, proposing to swap them for new first lien senior secured notes due 2031. The company also seeks consent to amend the indenture, eliminating most restrictive covenants. Approximately 94.5% of noteholders agreed to tender their notes, and 70.0% committed to purchasing up to $410.2 million in new notes. The offer expires November 27, 2026, with early submission rewards.